Literature DB >> 17187892

The role of degradant profiling in active pharmaceutical ingredients and drug products.

Karen M Alsante1, Akemi Ando, Roland Brown, Janice Ensing, Todd D Hatajik, Wei Kong, Yoshiko Tsuda.   

Abstract

Forced degradation studies are used to facilitate the development of analytical methodology, to gain a better understanding of active pharmaceutical ingredient (API) and drug product (DP) stability, and to provide information about degradation pathways and degradation products. In order to fulfill development and regulatory needs, this publication provides a roadmap for when and how to perform studies, helpful tools in designing rugged scientific studies, and guidance on how to record and communicate results.

Mesh:

Substances:

Year:  2006        PMID: 17187892     DOI: 10.1016/j.addr.2006.10.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  12 in total

1.  Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.

Authors:  Karen M Alsante; Kim Huynh-Ba; Steven W Baertschi; Robert A Reed; Margaret S Landis; Mark H Kleinman; Christopher Foti; Venkatramana M Rao; Paul Meers; Andreas Abend; Daniel W Reynolds; Biren K Joshi
Journal:  AAPS PharmSciTech       Date:  2013-11-27       Impact factor: 3.246

2.  Stability study on an anti-cancer drug 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid (CLEFMA) using a stability-indicating HPLC method.

Authors:  Dhawal Raghuvanshi; Gregory Nkepang; Alamdar Hussain; Hooman Yari; Vibhudutta Awasthi
Journal:  J Pharm Anal       Date:  2016-09-28

Review 3.  Development of forced degradation and stability indicating studies of drugs-A review.

Authors:  M Blessy; Ruchi D Patel; Prajesh N Prajapati; Y K Agrawal
Journal:  J Pharm Anal       Date:  2013-09-17

4.  Validation of a Stability-Indicating Spectrometric Method for the Determination of Sulfacetamide Sodium in Pure Form and Ophthalmic Preparations.

Authors:  Sofia Ahmed; Noureen Anwar; Muhammad Ali Sheraz; Iqbal Ahmad
Journal:  J Pharm Bioallied Sci       Date:  2017 Apr-Jun

5.  Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method.

Authors:  Sahar Zayed; Fathalla Belal
Journal:  Chem Cent J       Date:  2017-05-04       Impact factor: 4.215

6.  A Standardized Approach to Quantitative Analysis of Nicotine in e-Liquids Based on Peak Purity Criteria Using High-Performance Liquid Chromatography.

Authors:  Vinit V Gholap; Leon Kosmider; Matthew S Halquist
Journal:  J Anal Methods Chem       Date:  2018-08-09       Impact factor: 2.193

7.  Rapid Raman Spectroscopic Analysis of Stress Induced Degradation of the Pharmaceutical Drug Tetracycline.

Authors:  Domes Christian; Frosch Timea; Popp Juergen; Torsten Frosch
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

8.  Validation and uncertainty estimation of an ecofriendly and stability-indicating HPLC method for determination of diltiazem in pharmaceutical preparations.

Authors:  Fahimeh Sadeghi; Latifeh Navidpour; Sima Bayat; Minoo Afshar
Journal:  J Anal Methods Chem       Date:  2013-09-17       Impact factor: 2.193

9.  Determination of stress-induced degradation products of cetirizine dihydrochloride by a stability-indicating RP-HPLC method.

Authors:  Paloma Flórez Borges; Pilar Pérez Lozano; Encarna García Montoya; Montserrat Miñarro; Josep R Ticó; Enric Jo; Josep M Suñe Negre
Journal:  Daru       Date:  2014-12-09       Impact factor: 3.117

10.  Development and Validation of a UHPLC UV Method for the In-Process Control of Bosentan Monohydrate Synthesis.

Authors:  Marta Jatczak; Katarzyna Sidoryk; Magdalena Kossykowska; Wojciech Łuniewski; Joanna Zagrodzka; Elżbieta Lipiec-Abramska
Journal:  Chromatographia       Date:  2016-07-09       Impact factor: 2.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.